Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (33)

Advertisement

Research Article Free access | 10.1172/JCI106839

Thyroid Hormone Binding by Human Serum Prealbumin (TBPA). ELECTROPHORETIC STUDIES OF TRIIODOTHYRONINE-TBPA INTERACTION

Paul J. Davis, Barry S. Handwerger, and Robert I. Gregerman

Department of Medicine, Baltimore City Hospitals, Baltimore, Maryland 21224

Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Gerontology Research Center, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Davis, P. in: PubMed | Google Scholar

Department of Medicine, Baltimore City Hospitals, Baltimore, Maryland 21224

Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Gerontology Research Center, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Handwerger, B. in: PubMed | Google Scholar

Department of Medicine, Baltimore City Hospitals, Baltimore, Maryland 21224

Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Gerontology Research Center, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Gregerman, R. in: PubMed | Google Scholar

Published March 1, 1972 - More info

Published in Volume 51, Issue 3 on March 1, 1972
J Clin Invest. 1972;51(3):515–521. https://doi.org/10.1172/JCI106839.
© 1972 The American Society for Clinical Investigation
Published March 1, 1972 - Version history
View PDF
Abstract

Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [125I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). The T3-TBPA interaction has been confirmed at pH 9.0 and pH 7.4 in this electrophoretic demonstration of TBPA binding of T3 in serum. Purified human TBPA has also been shown to bind T3. Progressive additions of unlabeled thyroxine (T4) to serum containing tracer [125I]T3 displace T3 from TBG, its principal carrier, to TBPA and albumin; however, T4 loading does not lead to significant T3 displacement from TBPA even at T4 levels known to saturate TBPA. Loading of serum with unlabeled T3 results in displacement of more than 50% of [125I]T3 from TBPA, as well as from TBG, to albumin. Studies carried out with serum containing diphenylhydantoin (DPH) or MK-185, known inhibitors of T4 binding by TBG, also showed T3 displacement from TBG to TBPA and albumin. Although salicylate and tetraiodothyroacetic acid (TETRAC) displace T4 from sites on TBPA, they have only minimal effects on T3-TBPA interaction.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 515
page 515
icon of scanned page 516
page 516
icon of scanned page 517
page 517
icon of scanned page 518
page 518
icon of scanned page 519
page 519
icon of scanned page 520
page 520
icon of scanned page 521
page 521
Version history
  • Version 1 (March 1, 1972): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (33)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts